Related Experiment Video

Updated: Oct 19, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants

C Romagnoli1, E Zecca, G Vento

  • 1Division of Neonatology, Catholic University of the Sacred Heart, Rome, Italy. cromagnoli@rm.unicatt.it

Intensive Care Medicine
|September 2, 1999
PubMed

Insights

Early dexamethasone administration significantly reduced chronic lung disease (CLD) in high-risk preterm infants. This steroid treatment also shortened ventilation and oxygen needs but caused transient side effects.

Area of Science:

  • Neonatalogy
  • Pediatric Pulmonology
  • Pharmacology

Background:

  • Chronic lung disease (CLD) is a significant complication in preterm infants.
  • Early intervention strategies are crucial for improving outcomes in high-risk neonates.

Purpose of the Study:

  • To assess the efficacy of early dexamethasone administration in preventing CLD in high-risk preterm infants.
  • To identify and evaluate the side effects associated with early steroid use.

Main Methods:

  • A randomized clinical trial was conducted in a neonatal intensive care unit.
  • 50 high-risk preterm infants were randomized to receive either dexamethasone or a control (no steroid treatment).
  • Dexamethasone was administered intravenously for 7 days, starting after 72 hours of life.

Main Results:

  • The incidence of CLD was significantly lower in the dexamethasone group at 28 days and 36 weeks postconceptional age (p < 0.001).
  • Infants receiving dexamethasone required shorter durations of intubation and oxygen therapy (p < 0.001).
  • Transient side effects included hyperglycemia, hypertension, growth failure, and left ventricular hypertrophy.

Conclusions:

  • Early dexamethasone administration demonstrates potential in preventing CLD in preterm infants.
  • The use of early dexamethasone should be carefully considered and limited to high-risk preterm infants.
Abstract

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...